Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 17

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 17
---
'>6</div>

Risks Relating to Our Intellectual Property

| · | We may be unable to obtain or protect intellectual property rights relating to our product candidates. |

| · | If we fail to comply with our obligations in the licensing and collaboration agreements, our competitive position, business, financial 
 condition, results of operations and prospects could be harmed.                                                                        |

| · | Compliance with federal regulations such as “march-in” rights may limit our exclusive rights and our ability to contract 
 with non-U.S. manufacturers.                                                                                             |

| · | Patent terms may be inadequate to establish our competitive position on our drug candidates for an adequate amount of time. |

| · | We may not be able to protect our intellectual property rights throughout the world. |

| · | Changes in patent law could diminish the value of our patents and impair our ability to protect our drug candidate. |

| · | We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming 
 and unsuccessful, and our patents could be found invalid or unenforceable.                                                                |

| · | Our failure to identify relevant third-party patents or correctly interpret the relevance, scope or expiration of patents, we may 
 be subject to infringement claims or may not be able to develop our drug candidates.                                              |

| · | Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual 
 property rights.                                                                                                                         |

| · | We may be subject to claims by third parties asserting that we or our employees have infringed, misappropriated or otherwise violated 
 their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.                         |

| · | We may be subject to claims challenging the inventorship of our patents and other intellectual property. |

| · | Intellectual property rights do not necessarily address all potential threats. |

| · | Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of shares 
 of our Common Stock to decline.                                                                                                    |

Risks Relating to this Offering and Our Common Stock

| · | You may experience immediate and substantial dilution in the net tangible book value per share of our 
 Common Stock you purchase in this offering.                                                           |

| · | Our management will have broad discretion over the use of the net proceeds from this offering, may invest                               
 or spend the proceeds raised in this offering in ways with which you may not agree and the proceeds may not yield a significant return.